At AMCP Nexus 2025, policy experts Geni Tunstall, JD, and Adam Colborn, JD, provided an in-depth look at the political, legal, and regulatory developments shaping health care over the past year.
At AMCP Nexus 2025, policy experts Geni Tunstall, JD, and Adam Colborn, JD, provided an in-depth look at the political, legal, and regulatory developments shaping health care over the past year.
A guest expert from Asembia 2025 explores how reimagining limited drug distribution models in oncology can eliminate care fragmentation, enhance patient outcomes, and foster stronger collaboration among providers, pharmacies, payers, and...
A guest expert from Asembia 2025 explores how reimagining limited drug distribution models in oncology can eliminate care fragmentation, enhance patient outcomes, and foster stronger collaboration among providers, pharmacies, payers, and...
At Asembia 2025, industry experts from Cencora gathered to dissect the pressing challenges and evolving implementation framework of the Inflation Reduction Act’s (IRA) Maximum Fair Price (MFP) provision.
At Asembia 2025, industry experts from Cencora gathered to dissect the pressing challenges and evolving implementation framework of the Inflation Reduction Act’s (IRA) Maximum Fair Price (MFP) provision.
In a packed session at Asembia 2025, Brian Corvino, lead partner at Deloitte Consulting, and Blasine Penkowski, former chief strategic customer officer at Johnson & Johnson, walked attendees through key lessons from early implementation of...
In a packed session at Asembia 2025, Brian Corvino, lead partner at Deloitte Consulting, and Blasine Penkowski, former chief strategic customer officer at Johnson & Johnson, walked attendees through key lessons from early implementation of...
At Asembia 2025, Luke Greenwalt, vice president at IQVIA, presented a sweeping overview of the evolving health care and pharmaceutical landscape, highlighting critical trends for payers as the industry enters a period of accelerated change.
At Asembia 2025, Luke Greenwalt, vice president at IQVIA, presented a sweeping overview of the evolving health care and pharmaceutical landscape, highlighting critical trends for payers as the industry enters a period of accelerated change.
Discover the latest state-level pharmacy policy trends, including pharmacy benefit manager (PBM) regulations and utilization management practices, from the eye-opening AMCP Nexus 2024 session.
Discover the latest state-level pharmacy policy trends, including pharmacy benefit manager (PBM) regulations and utilization management practices, from the eye-opening AMCP Nexus 2024 session.
Explore the world of federal pharmacy benefit manager (PBM) legislation and its potential impact on stakeholders in this in-depth analysis presented by Ross Margulies, JD, MPH, Partner and Co-Chair Healthcare and Life Sciences Coverage &...
Explore the world of federal pharmacy benefit manager (PBM) legislation and its potential impact on stakeholders in this in-depth analysis presented by Ross Margulies, JD, MPH, Partner and Co-Chair Healthcare and Life Sciences Coverage &...
In an updated analysis presented at the 2023 ASCO Annual Meeting, researchers examined the frequency with which surrogate endpoints were used to support oncology approvals from 2006 to 2022.
In an updated analysis presented at the 2023 ASCO Annual Meeting, researchers examined the frequency with which surrogate endpoints were used to support oncology approvals from 2006 to 2022.
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Dairy and gluten intake had no substantial effects on disease activity and quality of life in a retrospective study of 186 patients with multiple sclerosis (MS). Researchers published their findings online in Multiple Sclerosis Journal –...
Dairy and gluten intake had no substantial effects on disease activity and quality of life in a retrospective study of 186 patients with multiple sclerosis (MS). Researchers published their findings online in Multiple Sclerosis Journal –...
Discover the impact of manual processes and staffing challenges on payer enrollment and credentialing workflows in the 2024 State of Payer Enrollment and Credentialing Report by Medallion.
Discover the impact of manual processes and staffing challenges on payer enrollment and credentialing workflows in the 2024 State of Payer Enrollment and Credentialing Report by Medallion.
IPF is a chronic, progressive interstitial lung disease that presents a significant burden to ~3 million patients worldwide. Despite ongoing challenges with IPF diagnosis and management, new therapies in development are showing promise.
IPF is a chronic, progressive interstitial lung disease that presents a significant burden to ~3 million patients worldwide. Despite ongoing challenges with IPF diagnosis and management, new therapies in development are showing promise.
A case study highlighted rare immune colitis associated with rituximab therapy in a patient with relapsing multiple sclerosis (RMS) and emphasizes the need for increased awareness and monitoring of this potential adverse effect in clinical...
A case study highlighted rare immune colitis associated with rituximab therapy in a patient with relapsing multiple sclerosis (RMS) and emphasizes the need for increased awareness and monitoring of this potential adverse effect in clinical...
In this interview, Katie Devlin, VP of Interoperability at Cotiviti, discusses the impact of major shifts like TEFCA and the CMS Interoperability Rule on health plans, emphasizing the importance of joining a QHIN to increase data...
In this interview, Katie Devlin, VP of Interoperability at Cotiviti, discusses the impact of major shifts like TEFCA and the CMS Interoperability Rule on health plans, emphasizing the importance of joining a QHIN to increase data...